AbbVie Announces It Has Received A Complete Response Letter From the FDA Regarding Biologics License Application For TrenibotulinumtoxinE; FDA Requests Additional Information About Manufacturing Processes, Does Not Identify Any Safety Or Efficacy Concerns And Does Not Request Additional Clinical Studies